Home » Research » Liv.52 DS (tablet,syrup)

Liv.52 DS (tablet,syrup)

Research papers: - Clinical Papers: 7

Clinical Papers

    Varied Hepatic Disorders

  1. Safety and Effectiveness of Liv.52 DS in Patients with Varied Hepatic Disorders: An Open-Label, Multi-centre, Phase IV Study
    Sachin K. Shivnitwar, General Medicine, D. Y. Patil Medical College, Pune, IND , Ishwar Gilada, Skin and Sexually Transmitted Diseases, Unison Medicare and Research Centre, Mumbai, IND, Atul V. Rajkondawar, Internal Medicine, Government Medical College, Nagpur, Nagpur, IND, Sandeep K. Ojha, Hyperbaric Medicine and Woundcare, Jayyush Hospital, Ahmedabad, IND , Sandeep Katiyar, Pulmonology Department, Apollo Spectra Hospital, Kanpur, IND, Navneet Arya, Ayurveda, Sri Sai Institute of Ayurvedic Research and Medicine, Bhopal, IND , U. V. Babu, Research and Development, Himalaya Wellness Company, Bengaluru, IND , Rajesh Kumawat, Medical Services and Clinical Development, Himalaya Wellness Company, Bengaluru, IND. Cureus 16(5): e60898.;2024.
    DOI 10.7759/cureus.60898

    Non-alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

  1. The Effect of Liv.52 DS in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Pilot, Randomized, Double-Blind, Placebo-Controlled, Clinical Study
    Umesh Jalihal, Department of Gastroenterology, Sapthagiri Institute of Medical Sciences & Research Centre, Bangalore, KA, India; Rajesh Amarnath Nanda, Department of Medical Gastroenterology, SRM Medical College Hospital and Research Centre, Kattankulathur, TN, India; Kuldeep Katariya, Department of Medicine, Jeevandan Hospital, Bhopal, MP, India; Balamurugan Ramanathan, Department of Diabetology, Kovai Diabetes Speciality Centre & Hospital, Coimbatore, TN, India; Rajesh Kumawat, Department of Medical Services & Clinical Development, Himalaya Wellness Company, Bengaluru, KA, India.
    Hepatic Medicine: Evidence and Research 2025:17 61-73.

  2. The Effects of Liv.52 DS Tablets on Various Liver Parameters in Non-Alcoholic Fatty Liver Disease: Preliminary Trend Identified from a Cumulative Efficacy Analysis.
    Sharad C. Shah, Department of Gastroenterology, J.J. Group of Hospitals, Mumbai, India, Prasanna S. Shah, Department of Gastroenterology, Breach Candy, Jaslok & Saifee Hospitals, Mumbai, India, Nusly P. J. Pocha, Medical Consultant to Air France, KLM and Lufthansa German Airlines, India, Gontar Siregar, Department of Internal Medicine, University of Sumatera Utara, Medan, Indonesia. Srikrishna H A, R&D, Himalaya Wellness Company (HWC), Bengaluru, India, Rajesh Kumawat, Head- Medical Services and Clinical Development, R&D, Himalaya Wellness Company (HWC), Bengaluru, India. International Journal of Pharmaceutical and Clinical Research 2022; 14(6); 739-751.

  3. A prospective, interventional clinical study to evaluate the safety and efficacy of Liv.52 DS in the management of non-alcoholic fatty liver disease.
    Gontar Siregar, Division of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Sumatera Utara, Medan, Indonesia, Rangesh Paramesh, Rajesh Kumawat, Palaniyamma D, Srikrishna HA, The Himalaya Drug Company, Makali, Bengaluru, India. European Journal of Clinical and Experimental Medicine 2021; 19 (2): 129–136.
    DOI: 10.15584/ejcem.2021.2.3

    Alcoholic Liver Disease (ALD)

  1. Clinical and Safety Evaluation of Liv.52 in Alcoholic Liver Disease: A Review
    Subramanian Ganesh, GE Clinic & Endoscopy Centre & MIOT Hospital, Chennai, India Neeraj Joshi, Nepal Mediciti Hospital and Nepal Cancer Hospital & Research Centre, Lalitpur, Nepal, Mukesh Kumar Jain, MG Medical College & Hospital, Jaipur, India, Lokendra Sharma, Department of Pharmacology, SMS Medical College, Jaipur, India, Anish Desai, Intellimed Healthcare Solutions, Mumbai, India, Mohamed Rafiq, Uddagiri Venkanna Babu and Rajesh Kumawat, Research and Development, Himalaya Wellness Company, Bengaluru, India. Gastroenterology Insights 2022, 13, 377–386.
    DOI: https://doi.org/10.3390/gastroent13040037

  2. Liv.52 DS Syrup in the Management of Alcoholic Hepatitis: An Open Label Study
    S Ganesh, Consultant Gastroenterologist and Hepatologist, Chennai, D Palaniyamma and Suprabha Hegde, Medical Advisor, Research Associate R&D Center, The Himalaya Drug Company, Makali, Bangalore. Indian Journal of Clinical Practice, Vol. 21, No. 12, May 2011: 645-649.

    Drug Induced Liver Injury (DILI)

  1. Role of Liv.52 DS Tablets as a Hepatoprotective Agent in Tuberculosis Patients Receiving Antitubercular Drugs: A Double Blind Placebo Controlled Study.
    Gotoviin Choijamts, Ch.Batsyren, Orkhon B, Otgontyr, Otoch Manramba Medical Institute, Ulaan Baatar, Mongolia, Narantstsetseg D, Oyunerdene X, Zagirjav T, Songino khairkhan district hospital, Mongolia, Erdenesuvd, Enkhbayar, Pyrevbazar Bayangol district hospital, Mongolia, Oyundelger, Tungalag, Nalaikh district hospital, Mongolia, Erdenetsetseg D, Enkhtsetseg, Baga nuur district hospital, Mongolia, Bilegmaa M, Dornogovi provincial hospital, Mongolia, Sarantuya S, Bayanzyrkh district hospital, Mongolia and Palaniyamma D, Department of Clinical trial and Medical Services, The Himalaya Drug Company, India. Journal of Liver and Clinical Research 5(1): 1042 (2018).
    DOI. https://doi.org/10.47739/2379-0830/1042